CSL (ASX:CSL) shares rose nearly 1% in morning trade Monday after the biotechnology company secured marketing authorization from Health Canada for Andembry as a once-monthly treatment for hereditary angioedema attacks in adult and pediatric patients aged 12 years and older.
Andembry is designed to target activated FXII, a plasma protein that plays a key role in the attacks, according to the company's Friday, Aug. 8 release.
Hereditary angioedema is a rare and potentially life-threatening genetic disorder characterized by recurrent and unpredictable attacks of swelling in various parts of the body.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。